Liposome-based delivery system for vaccine candidates: constructing an effective formulation.
Nanomedicine (Lond)
; 7(12): 1877-93, 2012 Dec.
Article
en En
| MEDLINE
| ID: mdl-23249332
ABSTRACT
The discovery of liposomes in 1965 by Bangham and coworkers changed the prospects of drug delivery systems. Since then, the application of liposomes as vaccine delivery systems has been studied extensively. Liposomal vaccine delivery systems are made up of nano- or micro-sized vesicles consisting of phospholipid bilayers, in which the bioactive molecule is encapsulated/entrapped, adsorbed or surface coupled. In general, liposomes are not immunogenic on their own; thus, liposomes combined with immunostimulating ligands (adjuvants) or various other formulations have been used as vaccine delivery systems. A thorough understanding of formulation parameters allows the design of effective liposomal vaccine delivery systems. This article provides an overview of various factors that influence liposomal immunogenicity. In particular, the effects of vesicle size, surface charge, bilayer composition, lamellarity, pegylation and targeting of liposomes are described.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fosfolípidos
/
Vacunas
/
Sistemas de Liberación de Medicamentos
/
Liposomas
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Año:
2012
Tipo del documento:
Article
País de afiliación:
Australia